Nasdaq:BCAB
BioAtla, Inc.
A clinical-stage biotech company leveraging proprietary technology platforms to develop novel therapeutics for cancer and neurological diseases.
Key Metrics
Investment Thesis
Bull Case
An investor might buy this stock if they believe in the transformative potential of BioAtla's proprietary drug discovery platform to identify blockbuster candidates that could eventually generate significant revenue upon commercialization. The narrowing annual losses suggest improving operational efficiency, and a successful clinical trial readout could result in a substantial re-rating of the company's valuation.
Bear Case
An investor should avoid this stock due to the high probability of cash burn outflow without any near-term revenue generation, leaving the company vulnerable to liquidity crises given its current cash position and long-term liabilities. The significant retained earnings deficit indicates past financial distress, and any setback in clinical development could severely damage shareholder value or lead to insolvency.
About BioAtla, Inc.
BioAtla, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics for serious diseases such as cancer and neurological disorders. The company utilizes advanced proprietary technologies to identify new drug targets and advance candidates through preclinical and clinical development stages in the United States and internationally. While currently operating without commercial revenue, the firm's financial structure reflects heavy investment in research and development activities aimed at bringing innovative medicines to patients.
Analysis
Management Discussion
Financial performance shows a narrowing loss trend with net income improving significantly from -$106.5M in 2022 to -$69.8M in 2024, driven by disciplined cost management and continued high investment in R&D totaling $63.1M. Despite the reduction in annual losses, operating cash flow remains deeply negative at -$71.9M, consuming the company's remaining cash balance of $49.0M and requiring future capital raises to sustain operations.
Industry Overview
The biotechnology industry is characterized by high-risk, high-reward dynamics where companies invest billions in R&D to develop novel therapies for diseases like cancer, often facing years of uncertainty before potential commercial success. Market leaders typically rely on patent protection and proprietary technology to establish barriers to entry, while smaller clinical-stage firms depend heavily on strategic partnerships and continuous capital raising to fund development.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $-11.0M |
| Gross Profit | $0 | $0 | $11.0M |
| Operating Expenses | $108.1M | $129.7M | $84.9M |
| Operating Income | $-108.1M | $-129.7M | $-73.9M |
| R&D | $79.3M | $103.7M | $63.1M |
| G&A | $28.8M | $26.0M | $21.8M |
| Stock-Based Comp | $14.6M | $13.5M | $8.9M |
| D&A | $1.2M | $1.2M | $925.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $0 | — | — |
| Interest Income | $1.6M | $6.3M | $3.4M |
| Pre-Tax Income | $-108.1M | $-129.7M | $-73.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-108.1M | $-129.7M | $-73.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-106.5M | $-123.5M | $-69.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-106.5M | $-123.5M | $-69.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $220.4M | $116.4M | $51.2M |
| Cash & Equivalents | $215.5M | $111.5M | $49.0M |
| Prepaid Expenses | $4.9M | $4.9M | $2.2M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $5.3M | $3.3M | $1.2M |
| PP&E (Net) | $2.7M | $1.6M | $678.0K |
| Operating Leases | $2.4M | $1.5M | $512.0K |
| Other LT Assets | $154.0K | $154.0K | $0 |
| Total Assets | $225.7M | $119.7M | $52.4M |
| Current Liabilities | $23.1M | $28.3M | $14.5M |
| Accounts Payable | $4.2M | $3.8M | $1.9M |
| Current Leases | $1.5M | $1.6M | $836.0K |
| Other Current Liab | $17.4M | $22.9M | $11.8M |
| Long-Term Liabilities | $22.3M | $20.6M | $23.6M |
| LT Operating Leases | $2.5M | $836.0K | $0 |
| Other LT Liab | $19.8M | $19.8M | $23.6M |
| Total Liabilities | $45.4M | $49.0M | $38.2M |
| Shareholders' Equity | $180.3M | $70.7M | $14.3M |
| Paid-In Capital | $473.1M | $486.9M | $500.3M |
| Retained Earnings | $-292.8M | $-416.3M | $-486.0M |
| Total L&E | $225.7M | $119.7M | $52.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-106.5M | $-123.5M | $-69.8M |
| Non-Cash Adjustments | $10.6M | $14.7M | $14.8M |
| Working Capital Changes | $5.5M | $4.7M | $-17.0M |
| Cash from Operations | $-90.4M | $-104.0M | $-71.9M |
| Cash from Investing | $-265.0K | $-98.0K | $0 |
| Cash from Financing | $61.2M | $77.0K | $9.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-29.5M | $-104.0M | $-62.4M |
| Beginning Cash | $245.0M | $215.5M | $111.5M |
| Ending Cash | $215.5M | $111.5M | $49.0M |
Frequently Asked Questions
How does BioAtla, Inc. make money?
The company operates primarily through a unified research and development segment focused on drug discovery, preclinical studies, and clinical trials across multiple therapeutic areas including oncology and neuroscience.
What are the main risks for BCAB?
The company faces substantial risk of total or partial failure of its drug candidates in clinical trials, potential dilution from future equity issuances given the large retained earnings deficit, inability to secure sufficient financing due to limited current assets and negative operating cash flow, and regulatory uncertainties inherent in bringing new drugs to market.
What is BCAB's competitive advantage?
BioAtla possesses a differentiated pipeline targeting unmet medical needs with high-value indications, utilizes cost-effective proprietary platforms for target identification, and maintains a lean operational structure to extend cash runway despite significant R&D expenditures.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.